Latest news with #spinalcordinjury
Irish Times
21-07-2025
- Health
- Irish Times
Writing about my trauma helps me - and my spinal cord recovery
After Tadhg Paul was left with no movement or feeling below the neck following a fall, there was a stage during nine months in hospital when he made peace with the prospect of dying. Staring up at the ceiling, he thought 'you have a lot of time to contemplate your life and the universe'. It prompted him to return to writing , which he had practised from childhood before a tech career took over. He has no doubt now that writing helped him embrace life again and regain mobility from his spinal cord injury, classed as grade B quadriplegia . Three years later, the 45-year-old man uses just a walking cane to make his way to an outdoor table at a south Co Dublin cafe on a hot July afternoon for this interview. READ MORE Dressed all in black, from sunglasses down, he talks about how the psychological journey back from injury has been bigger for him than the physical journey. Studies have shown that writing about stressful and traumatic events can significantly improve physical and emotional health. As a believer in the power of words, he found spinning them into poetry particularly therapeutic. 'Assistive technology was a liberator for me,' Tadhg says, 'just with the little Alexa in the corner, I was able to consume podcasts and audiobooks. 'Eventually I was able to, with voice control initially, use my phone and then the computer.' Therapists talk about the value of 'journaling' but, as somebody diagnosed in adulthood with ADHD, Paul says it does not work for him. He prefers writing poetry. Tadgh Paul, in Greystoneshas regained partial mobility and was greatly helped, he says, by the therapy of writing. Photograph: Nick Bradshaw 'It's been very healing for me. It's almost like I picked [my trauma] up, grasped it, examined it, brought it into the light and sort of declared it to the world.' Initially, he was writing it for himself, but he believes bringing it to a wider audience is part of the healing process. Using Paul as a pen surname, he joined the SeaScribes writing group, which meets weekly in the Mermaid County Wicklow Arts Centre in Bray . He is one of eight writers who contributed to their first anthology launched in July, Cargo of the Soul. All six of his pieces concern issues, which he says were 'put inside a box', repressed rather than dealt with. These include an early realisation about being gay, grief at the death of a soul mate and facing his own mortality. 'You kind of bare all to the world and you say, 'this is my trauma and here's what it means to me'.' While still in hospital, he created a website to post his poetry. 'Even if I was stuck in a bed, I could have a very imperfect digital engagement with the world,' he says. After six months in acute hospital care, he was transferred to the National Rehabilitation Hospital where his days were much busier as staff worked over three months to get him back on his feet. Occasionally, he still uses a wheelchair, so has moved in with his parents in Greystones , Co Wicklow , due to not being able to find suitable private rental accommodation. He was able to return to work last November but on reduced hours. Now, he also has to cope with fluctuating pain. 'I really struggle with the weather changes. It used to be that I needed two painkillers to get out of bed in the morning. I'm managing that with a different pain therapy at the moment.' As well as SeaScribes, Paul participates in an online writing group, Strange Birds. Both spaces have been important, he says, in allowing to him to 'share something quite personal and intimate' and to 'hone the quality'. It also gives him a chance 'to see how it lands – and it lands differently with everybody'. SeaScribes was founded, post-Covid, by psychologist Rita Wall, who writes under the pen name Mairead de Bhal. Keen to set up an emerging writers' group in the area, the Mermaid Arts Centre proved to be a perfect meeting place. [ Write now: Nine writers share advice on how to get started Opens in new window ] The centre's artistic director and CEO, Aoife Demel, says 'creativity for all' and 'the power and value of the arts for wellbeing' are among their core beliefs. Mermaid Arts Centre runs a programme of 'take part' events to allow people of all ages 'to engage with their creative sides, fostering wellbeing, connectivity and relevance'. When she was setting up the group, de Bhal says prospective members just had to have an interest in writing. Members critique each other's work and support the pursuit of publication, whether it is in a local newspaper or more highbrow journals – and now their self-published book. Taking up the anthology's theme of cargo, de Bhal wrote two stories from long-forgotten childhood memories from living in the North. Her father, a bank manager transferred from Dublin, was held up at gunpoint when travelling to a sub-office with cash; the family then had to leave their home above the bank in Strabane , Co Tyrone , which was later blown up. She wouldn't call the resulting story therapy, but says it was certainly a way of processing childhood memories. Fellow SeaScribe Lesley Smith describes her writing, mostly poetry, as 'a way of sharing things without having to say [them] verbally'. Amongst its uses, she she said she values it as a mental health support. 'I don't declare when I write what's me and what's observation; what's real and what's fiction. There's always a nervousness when you're sharing things that you would be judged, particularly when it's mental health stuff.' Lesley Smith says writing can be a support to mental health At the time of writing for the book, Smith, who is retired from the health service, was coping with several personal challenges. Her poem titled My Cargo reflects the worries she had about losing her memory and watching a family member living with Alzheimer's . Another personal challenge was coping with the decision of her brother, who was living with a terminal illness in Canada, to avail of what she terms ' assisted suicide ', which is legal there. 'I was absolutely stunned at the effect it had on me because I absolutely agree with the concept; I agreed with his decision... but I realised that what it does is it starts the grieving process way before you lose the person.' As it happened, his condition suddenly deteriorated and he died naturally overnight last February. Meanwhile, experience of self-doubt and 'scam' warnings from concerned friends, upon falling for a man, Thomas, whom she met at an airport bus stop, is seared into her short story, Awoken. 'Isn't it a terrible thing in our society that when you get passed a certain age, if there's some sort of romantic attachment, it's seen as being negative,' she says. 'It's like there is a 'date stamp' on love.' Thomas died unexpectedly during a trip home to his native India in May, just as they were arranging to formally live together in Gran Canaria, after having a relationship for more than two years. 'We had all these plans and we were committed to each other. Then, as they say, life took another turn.' Writing truth can indeed be stranger than fiction. Can writing help your mind? Psychotherapist Aine Connaire knows the benefit, both personally and professionally, of writing down thoughts to relieve the torment of a swirling mind. 'It's amazing the mind then, for some reason, feels like it doesn't have to hold on to it any more. And then when we do write it down, we're able to see it from a different perspective.' What is referred to as 'journaling' is a way to explore your inner world and can be done at home alone, or in conjunction with therapy sessions. It is not the same as keeping a diary, which is traditionally recording details of your day, or an event, and creates a finished piece. 'It's like your journal becomes a friend'. Photograph: Getty Images 'Journal writing is very different; you're writing to engage in a process and it is a therapeutic process.' It is convenient, free and you don't need somebody willing to listen, points out Connaire, who runs a counselling practice in Mullingar, Co Westmeath. She also offers an online introductory course to therapeutic journaling, Writing to Heal. 'It's like your journal becomes a friend. Emotions are thoughts that we may find difficult to tolerate and they can be put down in a journal without judgement.' Unstructured journaling involves free flow writing. 'You're opening up a page and beginning to write and just seeing what comes up to the surface and continuing to let that flow.' If that blank page or screen seems too daunting, a structure, such as gratitude journaling, or a letter to anyone or anything, can get you started. Connaire also recommends 'dialogue writing'. Instead of the one-sided nature of a letter, this conversational approach fills in imagined responses from the person or object being addressed. [ Writing can brighten and enlighten – just let it flow Opens in new window ] 'It's really interesting what comes up, because we have these conversations in our mind all the time.' Many people who come to therapy are unsure of why they are feeling a certain way, she says. 'If you dialogue with the emotion it's amazing what can be uncovered.' People can also interact with an illness or pain. Trauma or grief can be held in a particular part of our body, she explains, and that can manifest as physical illness. If clients want to go through their writing with her, that can be helpful. However, it's not something they have to do 'because a journal contains huge vulnerability and raw emotions, thoughts that they might not feel ready to share with me at that time'. For people who are afraid that if they write their thoughts down, somebody else may find them to read, the paper can be burnt afterwards, she suggests, or the words deleted from a screen. Creating notes on a mobile phone has become a popular method of journaling because people tend to have a lock on it. Connaire's note of caution for somebody journaling without seeing a therapist, is to ensure they have access to support if necessary in dealing with trauma. 'You don't want to open up and re-traumatise yourself and not have that support in place.'
Yahoo
17-07-2025
- Business
- Yahoo
NervGen Announces Leadership Transition to Support Strategic Growth and Expansion
Chairman Dr. Adam Rogers Appointed Interim CEO Following Landmark Positive Chronic Spinal Cord Injury Trial Results Vancouver, British Columbia--(Newsfile Corp. - July 17, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF) (the "Company"), a clinical-stage biotechnology company developing innovative therapies for spinal cord injury (SCI) and other nervous system disorders, today announced a leadership transition as the Company enters the next phase of development for its first and potential best-in-class candidate, NVG-291. President and Chief Executive Officer Mike Kelly has stepped down as a director and officer of the Company and Dr. Adam Rogers, Chair of the Board and representative of NervGen's largest shareholder, has been appointed Interim CEO. "We are deeply grateful to Mike for his exceptional leadership during a pivotal time for NervGen," said Dr. Adam Rogers, Chairman and Interim CEO of NervGen. "Under Mike's guidance, the Company advanced NVG-291 through landmark proof-of-concept topline results from the chronic cohort of the CONNECT SCI study. Mike's leadership established the organizational framework needed for future growth and set a clear strategic direction to position NervGen one step closer to addressing its mission of transforming the lives of individuals living with spinal cord injury." "The chronic cohort of the CONNECT SCI study represents the strongest signal of efficacy observed to date in spinal cord injury," Dr. Rogers added. "We are entering the most exciting and important phase in NervGen's history and are committed to proactively engaging with regulators and the SCI community to advance NVG-291 toward its full potential." Regarding his departure, Mr. Kelly commented, "It's been an honor to lead NervGen during a pivotal time of clinical and operational growth. I'm proud of the team we've built and the opportunity to successfully advance NVG-291 through an unprecedented proof-of-concept efficacy trial in chronic spinal cord injury. With positive data in hand, NervGen is well-positioned for future growth. I remain a strong advocate of the Company and its mission to redefine the standard of care in spinal cord injury." The leadership transition comes as NervGen continues to analyze data from the chronic cohort of the CONNECT SCI study in preparation for sharing additional insights and engaging in regulatory discussions. About NVG-291NervGen holds exclusive worldwide rights to NVG-291, a first- and potential best-in-class therapeutic peptide targeting nervous system repair. NVG-291's technology is licensed from Case Western Reserve University and is based on academic studies that demonstrated the preclinical efficacy of NVG-291-R, the rodent variant of NVG-291, in animal models of spinal cord injury. These studies implicated multiple potential molecular and cellular mechanisms by which NVG-291-R promotes neurorepair and functional improvement in both central and peripheral nervous system injury models. The implicated mechanisms include the promotion of neuronal sprouting, or plasticity, remyelination, and promotion of a non-inflammatory phenotype in the microglial cells. NervGen has received Fast Track designation from the FDA and Orphan Designation from the EMA for NVG-291 in individuals with spinal cord injury. About NervGenNervGen (TSXV: NGEN) (OTCQB: NGENF) is a clinical-stage biotechnology company dedicated to developing innovative therapies to promote nervous system repair in settings of neurotrauma and neurologic disease. The Company is testing the clinical efficacy of its lead candidate, NVG-291, in the Phase 1b/2a CONNECT SCI Study clinical trial in spinal cord injury. Topline data from the chronic cohort (1-10 years post-injury) of this trial showed that NVG-291 met its primary endpoint and demonstrated strong trends in functional assessments. Continued analysis of data from the chronic cohort is ongoing. Enrollment in the subacute cohort (20-90 days post-injury) of the trial continues, and more information about participation in the subacute study is available at In addition, the company has initiated preclinical testing of concept evaluation of its pipeline candidate, NVG-300, in models of ischemic stroke and spinal cord injury. For more information about NervGen, visit and follow NervGen on X and LinkedIn for the latest news on the company. ContactsHuitt Tracey, Investor Relations htracey@ Bill Adams, Chief Financial Officer info@ Christy CurranSam Brown Healthcare Communications christycurran@ Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Cautionary Note Regarding Forward-Looking Statements This news release may contain "forward-looking information" and "forward-looking statements" within the meaning of applicable Canadian and United States securities legislation (collectively, "forward-looking statements"). Such forward-looking statements herein include but are not limited to, the Company's current and future plans, expectations and intentions, results, levels of activity, performance, goals or achievements, or any other future events or developments constitute forward-looking statements, and the words "may", "will", "would", "should", "could", "expect", "plan", "intend", "trend", "indication", "anticipate", "believe", "estimate", "predict", "likely" or "potential", or the negative or other variations of these words or other comparable words or phrases, are intended to identify forward-looking statements. Forward-looking statements include, without limitation, statements relating to: the Company's potential best-in-class candidate, NVG-291; the future growth of the Company; the Company's mission of transforming the lives of individuals living with spinal cord injury; the objectives, planned clinical endpoints, timing, expected rate of enrollment, and study design of our Phase 1b/2a clinical trial of NVG-291 in individuals with spinal cord injury; the future development plans and benefits of NVG-291; the development plans and prospective target indications for NVG-300; and the creation of neuroreparative therapeutics to promote nervous system repair in settings of neurotrauma and neurologic disease. Forward-looking statements are based on estimates and assumptions made by the company in light of management's experience and perception of historical trends, current conditions and expected future developments, as well as other factors that we believe are appropriate and reasonable in the circumstances. In making forward-looking statements, we have relied on various assumptions, including, but not limited to: our ability to obtain future funding on favorable terms or at all; the accuracy of our financial projections; obtaining positive results in our clinical and other trials; our ability to obtain necessary regulatory approvals; our ability to arrange for the manufacturing of our product candidates and technologies; and general business, market and economic conditions. Many factors could cause our actual results, level of activity, performance or achievements or future events or developments to differ materially from those expressed or implied by the forward-looking statements, including without limitation, a lack of revenue, insufficient funding, reliance upon key personnel, the uncertainty of the clinical development process, competition, and other factors set forth in the "Risk Factors" section of the company's most recently filed prospectus supplement, short form base shelf prospectus, annual information form, financial statements and management discussion and analysis all of which can be found on NervGen's profile on SEDAR+ at All clinical development plans are subject to additional funding. Readers should not place undue reliance on forward-looking statements made in this news release. Furthermore, unless otherwise stated, the forward-looking statements contained in this news release are made as of the date of this news release, and we have no intention and undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement. To view the source version of this press release, please visit Sign in to access your portfolio
Yahoo
07-07-2025
- Business
- Yahoo
NervGen Provides Quarterly "At-The-Market" Equity Program and Grant of Options Update
Vancouver, British Columbia--(Newsfile Corp. - July 7, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF) ("NervGen" or the "Company"), a clinical-stage biotech company dedicated to developing innovative treatments for spinal cord injury (SCI) and other neurological conditions, today provided a quarterly update with respect to the Company's previously announced at-the-market equity program (the "ATM Program") launched on December 19, 2025. The ATM Program allows the Company to issue and sell common shares in the capital of the Company (the "Common Shares") to the public from time to time through Stifel Nicolaus Canada Inc. (the "Agent"), at the Company's discretion and subject to regulatory requirements. During the quarterly period ended June 30, 2025, the Company issued and sold 385,200 Common Shares under the ATM Program at a weighted average price of $2.95 per Common Share, for aggregate gross proceeds of $1,134,466. The Company paid cash placement fees of $22,689 to the Agent, resulting in aggregate net proceeds of $1,111,777. The Company announced as well that it granted 200,000 stock options (the "Options") to a director of the company. The Options are exercisable at a price of $3.55 per share and are exercisable for a period of five years and vest equally every three months over a one-year period. All options have been granted in accordance with the policies of the TSX Venture Exchange and the conditions of the company's stock option plan. About NervGenNervGen (TSXV: NGEN) (OTCQB: NGENF) is a clinical-stage biotech company dedicated to developing innovative treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company is testing the clinical efficacy of its lead candidate, NVG-291, in the Phase 1b/2a CONNECT SCI Study clinical trial in spinal cord injury. Topline data from the chronic cohort (1-10 years post-injury) of this trial showed that NVG-291 met its primary endpoint and demonstrated strong trends in a secondary endpoint assessing hand function. Complete analysis of the chronic cohort is ongoing. Enrollment in the subacute cohort (20-90 days post-injury) of the trial continues, and more information about participation in the subacute study is available at In addition, the company has initiated preclinical test of concept evaluation of its pipeline candidate, NVG-300, in models of ischemic stroke and spinal cord injury. For more information about NervGen, visit and follow NervGen on X and LinkedIn for the latest news on the company. Contacts Huitt Tracey, Investor Relationshtracey@ Bill Adams, Chief Financial Officerinfo@ Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Cautionary Note Regarding Forward-Looking StatementsThis news release contains "forward-looking information" and "forward-looking statements" within the meaning of applicable Canadian securities legislation. Such forward-looking statements and information herein include but are not limited to, the Company's current and future plans, expectations and intentions, results, levels of activity, performance, goals or achievements, or any other future events or developments constitute forward-looking statements, and the words "may", "will", "would", "should", "could", "expect", "plan", "intend", "trend", "indication", "anticipate", "believe", "estimate", "predict", "likely" or "potential", or the negative or other variations of these words or other comparable words or phrases, are intended to identify forward-looking statements. Forward-looking statements include, without limitation, statements relating to: the issuance, sale and distribution of Common Shares under the ATM Program. Forward-looking statements are based on estimates and assumptions made by the Company in light of management's experience and perception of historical trends, current conditions and expected future developments, as well as other factors that we believe are appropriate and reasonable in the circumstances. In making forward-looking statements, we have relied on various assumptions, including, but not limited to: that the Company will receive the necessary regulatory approvals for the ATM Program; that the Company will be able to use the proceeds from the ATM Program as anticipated; our ability to obtain future funding on favourable terms or at all; the accuracy of our financial projections; obtaining positive results in our clinical and other trials; our ability to obtain necessary regulatory approvals; our ability to arrange for the manufacturing of our product candidates and technologies; and general business, market and economic conditions. Many factors could cause our actual results, level of activity, performance or achievements or future events or developments to differ materially from those expressed or implied by the forward-looking statements, including without limitation, the Company being unable to use the proceeds from the ATM Program as anticipated, failure to receive the requisite regulatory approvals for the ATM Program, a lack of revenue, insufficient funding, reliance upon key personnel, the uncertainty of the clinical development process, competition, and other factors set forth in the "Risk Factors" section of the company's most recently filed prospectus supplement, short form base shelf prospectus, annual information form, financial statements and management discussion and analysis all of which can be found on the Company's profile on SEDAR+ at All clinical development plans are subject to additional funding. Readers should not place undue reliance on forward-looking statements made in this news release. Furthermore, unless otherwise stated, the forward-looking statements contained in this news release are made as of the date of this news release, and we have no intention and undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement. To view the source version of this press release, please visit Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
02-07-2025
- Business
- Yahoo
Medical Exoskeleton Market Poised for Growth, Estimated to Hit USD 2,267.2 Million by 2032
The Medical Exoskeleton Market presents strong opportunities due to growing demand for rehabilitation solutions, rising spinal cord injury cases, advances in robotic technology, and increased adoption in elderly care and physical therapy settings Burlingame, CA, July 02, 2025 (GLOBE NEWSWIRE) -- The Global Medical Exoskeleton Market is estimated to be valued at USD 538.4 Mn in 2025 and is expected to reach USD 2,267.2 Mn in 2032, exhibiting a compound annual growth rate (CAGR) of 22.8% from 2025 to 2032. Medical exoskeletons are wearable systems designed to support movement and enhance physical strength. These devices assist individuals with mobility challenges such as muscle weakness or spinal injuries in walking, standing, lifting, and participating in rehabilitation or work-related tasks. Market growth is fueled by the rising number of spinal cord injuries, increasing orthopaedic conditions, and the expanding elderly population. Request Sample Report: Global Medical Exoskeleton Market Key Takeaways According to Coherent Market Insights (CMI), the global medical skeleton market size is expected to grow more than fourfold, from USD 538.4 Mn in 2025 to USD 2,267.2 Mn by 2032. Global demand for medical exoskeletons is anticipated to increase at a prolific CAGR of 22.8% during the forecast period. Based on type, lower body exoskeletons segment is expected to dominate the industry, holding a market share of 43.2% in 2025. North America is projected to account for nearly two-fifths of the global medical exoskeleton market share in 2025. Europe medical exoskeleton market is estimated to be valued at around USD 150. 75 Mn by 2025. Asia Pacific is poised to record fastest growth during the assessment period. This is due to rising incidence of mobility impairments and disabilities, as well as increasing acceptance and adoption of medical exoskeletons. Get Instant Access! Purchase Research Report and Receive a 25% Discount: Rising Prevalence of Disabilities and Neurological Disorders Fueling Market Growth Coherent Market Insights' latest global medical exoskeleton market research report provides insights into key factors driving the industry's growth. One such key growth driver is the increasing incidence of neurological disorders and physical disabilities. According to the World Health Organization (WHO), over 3 billion people worldwide are living with a neurological condition. This rise in neurological disorders like stroke, multiple sclerosis, Parkinson's disease, and cerebral palsy is expected to boost demand for medical exoskeletons. Medical exoskeletons are designed to assist or enhance human movement. They have the tendency to support rehabilitation by assisting weakened muscles. These wearable mechanical devices consist of structural components, control systems, sensors, motors, and actuators that work together to mimic human motion. High Cost and Regulatory Hurdles Limiting Market Growth The global medical exoskeleton market outlook indicates strong future growth. However, high cost of medical exoskeletons and regulatory challenges are expected to limit market expansion to some extent. Advanced medical exoskeletons are quite expensive, costing thousands of dollars. This high cost deters patients with disabilities from opting for medical exoskeletons, leading to reduced market demand. Similarly, medical exoskeletons must undergo rigorous and often lengthy regulatory approval processes. These processes can delay product launches and increase development costs, potentially hindering the global medical exoskeleton market growth. Ongoing Innovations Creating Lucrative Growth Opportunities Innovation remains a prime area of focus for medical exoskeleton companies to capitalize on emerging opportunities. Leading industry players are constantly integrating AI, IoT, sensors, and lightweight materials in their products to enhance functionality, comfort, and adaptability of medical exoskeletons. Similarly, advancements in battery technologies and wearable designs are making medical exoskeletons more attractive, accessible, and user-friendly. These innovations are expected to play a key role in boosting the overall global medical exoskeleton market value during the forecast period. Impact of AI on the Global Medical Exoskeleton Market Artificial intelligence (AI) is creating strides in the global medical exoskeleton market. This advanced technology is transforming rigid assistive devices into adaptive, intelligent companions. AI enables exoskeletons to anticipate users' intentions as well as deliver real-time motion adjustments and reduce fall risk. This heightened responsiveness is particularly beneficial in rehabilitation. AI-enabled remote monitoring and cloud integration allow clinicians to track progress and adjust protocols virtually. This technology helps extend rehabilitation and mobility support beyond traditional healthcare settings, thereby unlocking new growth opportunities in the medical exoskeleton market. Emerging Global Medical Exoskeleton Market Trends Increasing geriatric population is expected to uplift demand for medical exoskeletons, as older adults are more susceptible to mobility impairments and musculoskeletal conditions like osteoporosis and arthritis. This demographic shift is increasing the need for effective rehabilitation solutions and mobility assistance technologies. Rising cases of spinal cord injuries is positively impacting sales of medical exoskeletons. As more people suffer from spinal cord injuries, they need assistive and rehabilitative technologies like medical exoskeletons. These technologies play a crucial role in supporting mobility, enhancing rehabilitation outcomes, and improving quality of life for individuals with spinal cord injuries. There is a rapid transition from stationary exoskeletons to mobile ones. Companies are striving to develop mobile medical exoskeletons to meet evolving needs and preferences of end users. Leading companies are also focusing on developing exoskeletons for home care settings. This will likely contribute to the expansion of the global medical exoskeleton industry in the coming years. Get Customization on this Report: Analyst's View said Manisha Vibhute, a senior analyst at CMI. Current Events and Their Impact on the Global Medical Exoskeleton Market Event Description and Impact U.S. Department of Veterans Affairs Expands Exoskeleton Coverage Description: The U.S. Department of Veterans Affairs has expanded reimbursement eligibility for powered exoskeletons used in spinal cord injury rehabilitation. Impact: This move is expected to open a significant reimbursement pathway, increasing accessibility for U.S. veterans and encouraging wider adoption of exoskeletons in hospitals and rehabilitation centers. Breakthroughs in Exoskeleton Technologies Description: In February 2025, Chulalongkorn University introduced its 'Exoskeleton Wheelchair,' a hybrid robotic suit designed to assist elderly individuals and people with mobility challenges in sitting, standing, and walking. Impact: Such technological advancements are likely to accelerate innovation and fuel market growth in the medical exoskeleton industry. European Union's AI Act Implementation Begins Description: The EU started phased enforcement of the AI Act, with medical AI-powered devices classified under strict regulatory scrutiny. Impact: Companies developing AI-integrated exoskeletons must comply with rigorous transparency and safety criteria. Competitor Insights Key companies listed in the global medical exoskeleton market report: BIONIK ReWalk Robotics Ekso Bionics Suit X PARKER HANNIFIN CORP Rex Bionics Ltd B-Temia CYBERDYNE INC. ExoAtlet Wandercraft Key Developments In April 2025, Lifeward Ltd. announced the U.S. launch of the ReWalk 7 Personal Exoskeleton for people with spinal cord injuries. The new device, featuring enhanced features, is designed to provide a more functional and personalized walking experience. In February 2025, Wandercraft initiated a new clinical trial for its groundbreaking Personal Exoskeleton at the James J. Peters VA Medical Center in the Bronx, NY. It is the world's first self-balancing exoskeleton developed for personal use. In December 2024, researchers at the Korea Advanced Institute of Science and Technology developed a lightweight wearing robot for paraplegic patients. The new Iron Man Robot, named WalkON Suit F1, can approach paraplegic patients and lock itself onto them, enabling them to walk, climb staircases, and maneuver obstacles. Global Medical Exoskeleton Market Segmentation: By Type Lower Body Exoskeletons Upper Body Exoskeletons Full Body Exoskeletons Others (Soft Exoskeletons, Active Exoskeletons, Passive Exoskeletons) By Mobility Mobile Exoskeletons Stationary Exoskeletons Fixed Exoskeletons By End User Rehabilitation Centers Hospitals Long Term Care Centers Homecare Settings Others (Industrial Sites, Military) By Region North America Europe Asia Pacific Latin America Middle East and Africa Read More Reports: Bionic Prosthetics Market Size, Share & Trend Analysis Report (2025-2032)Exoskeleton Market Size, Share, Trends & Opportunities for 2025 to 2032Military Exoskeleton Market Analysis and Forecast for 2025-2032 Our Trusted Partners:Worldwide Market Reports, Coherent MI, Stratagem Market InsightsGet Recent News: CONTACT: About Us: Coherent Market Insights leads into data and analytics, audience measurement, consumer behaviors, and market trend analysis. From shorter dispatch to in-depth insights, CMI has exceled in offering research, analytics, and consumer-focused shifts for nearly a decade. With cutting-edge syndicated tools and custom-made research services, we empower businesses to move in the direction of growth. We are multifunctional in our work scope and have 450+ seasoned consultants, analysts, and researchers across 26+ industries spread out in 32+ countries. Contact Us: Mr. Shah Coherent Market Insights 533 Airport Boulevard, Suite 400, Burlingame, CA 94010, United States US: + 12524771362 UK: +442039578553 AUS: +61-2-4786-0457 India: +91-848-285-0837 Email: sales@ Website: For Latest Update Follow Us: LinkedIn | Facebook | Twitter
Yahoo
01-07-2025
- Business
- Yahoo
NervGen Announces Clinical Leadership Transition as NVG-291 Continues to Advance Toward Late-Stage Development and Regulatory Milestones
Vancouver, British Columbia--(Newsfile Corp. - July 1, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing neuroreparative therapeutics, today announced that Daniel Mikol, MD, Ph.D., has resigned from his position as Chief Medical Officer in order to pursue new opportunities. Randall Kaye, MD, who was recently appointed Chief Medical Advisor, will increase the scope of his role as the company initiates a search for Dr. Mikol's replacement. "We thank Dan for progressing NVG-291 through the chronic cohort of our Phase 1b/2a clinical trial," said Mike Kelly, NervGen's President & CEO. "We are also grateful for the support of Randall, an industry veteran, as we complete the full data analysis of the chronic cohort and prepare for regulatory engagement." "It has been a pleasure to complete a successful study in chronic cervical spinal cord injury," said Dr. Mikol. "The positive topline results represent exciting progress and new hope for individuals living with spinal cord injury. NervGen is well poised to continue advancing this important program for the spinal cord injury community." NervGen is initiating a search for a new chief medical officer to lead NVG-291 and other potential future programs through clinical development toward regulatory approval. About NVG-291NervGen holds exclusive worldwide rights to NVG-291, a first-in-class therapeutic peptide targeting nervous system repair. NVG-291's technology is licensed from Case Western Reserve University and is based on academic studies that demonstrated the preclinical efficacy of NVG-291-R, the rodent prototype of NVG-291, in animal models of spinal cord injury. These studies implicated several potential molecular and cellular mechanisms by which NVG-291-R promotes neurorepair and functional improvement in both central and peripheral nervous system injury models. The implicated mechanisms include the promotion of neuronal sprouting, or plasticity, remyelination, and promotion of a non-inflammatory phenotype in the microglial cells. NervGen has received Fast Track designation from the FDA for NVG-291 in individuals with spinal cord injury. About NervGenNervGen (TSXV: NGEN) (OTCQB: NGENF) is a clinical-stage biotech company dedicated to developing innovative treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company is testing the clinical efficacy of its lead candidate, NVG-291, in a Phase 1b/2a clinical trial in spinal cord injury. Topline data from the chronic cohort (1-10 years post-injury) of this trial showed that NVG-291 met its primary endpoint and demonstrated promising changes in a secondary endpoint assessing hand function. Enrollment in the subacute cohort (20-90 days post-injury) of the trial continues, and more information about participation in the subacute study is available at In addition, the company has initiated preclinical test of concept evaluation of its pipeline candidate, NVG-300, in models of ischemic stroke and spinal cord injury. For more information about NervGen, visit and follow NervGen on X and LinkedIn for the latest news on the company. Contacts Huitt Tracey, Investor Relationshtracey@ Bill Adams, Chief Financial Officerinfo@ Christy CurranSam Brown Healthcare Communicationschristycurran@ Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Cautionary Note Regarding Forward-Looking StatementsThis news release may contain "forward-looking information" and "forward-looking statements" within the meaning of applicable Canadian and United States securities legislation (collectively, "forward-looking statements"). Such forward-looking statements herein include but are not limited to, the Company's current and future plans, expectations and intentions, results, levels of activity, performance, goals or achievements, or any other future events or developments constitute forward-looking statements, and the words "may", "will", "would", "should", "could", "expect", "plan", "intend", "trend", "indication", "anticipate", "believe", "estimate", "predict", "likely" or "potential", or the negative or other variations of these words or other comparable words or phrases, are intended to identify forward-looking statements. Forward-looking statements include, without limitation, statements relating to: the expected support for the company from the expanded role of our Chief Medical Advisor in the interim period prior to completing the search for a successor chief medical officer; our anticipated regulatory interactions; the objectives, planned clinical endpoints, timing, expected rate of enrollment, and timing of data readout and study design of our Phase 1b/2a clinical trial of NVG-291 in individuals with spinal cord injury; the future development plans and benefits of NVG-291; the development plans and prospective target indications for NVG-300 and other future programs; and the creation of neuroreparative therapeutics to promote nervous system repair in settings of neurotrauma and neurologic disease. Forward-looking statements are based on estimates and assumptions made by the company in light of management's experience and perception of historical trends, current conditions and expected future developments, as well as other factors that we believe are appropriate and reasonable in the circumstances. In making forward-looking statements, we have relied on various assumptions, including, but not limited to: our ability to obtain future funding on favourable terms or at all; the accuracy of our financial projections; obtaining positive results in our clinical and other trials; our ability to obtain necessary regulatory approvals; our ability to arrange for the manufacturing of our product candidates and technologies; and general business, market and economic conditions. Many factors could cause our actual results, level of activity, performance or achievements or future events or developments to differ materially from those expressed or implied by the forward-looking statements, including without limitation, a lack of revenue, insufficient funding, reliance upon key personnel, the uncertainty of the clinical development process, competition, and other factors set forth in the "Risk Factors" section of the company's most recently filed prospectus supplement, short form base shelf prospectus, annual information form, financial statements and management discussion and analysis all of which can be found on NervGen's profile on SEDAR+ at All clinical development plans are subject to additional funding. Readers should not place undue reliance on forward-looking statements made in this news release. Furthermore, unless otherwise stated, the forward-looking statements contained in this news release are made as of the date of this news release, and we have no intention and undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement. To view the source version of this press release, please visit Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
